Filtered By:
Source: BMJ Open
Drug: Zivast
Countries: Taiwan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging
Introduction
Dual antiplatelet therapy and high-intensity statins are the mainstay treatment in patients with acute stage, symptomatic intracranial atherosclerotic stenosis (ICAS). Alirocumab is a monoclonal antibody that can inhibit proprotein convertase subtilisin–kexin type 9 and effectively lower low-density lipoprotein cholesterol levels with less side effects than statins. We hypothesise that alirocumab treatment in addition to statin therapy could stabilise intracranial plaque and reduce arterial stenosis.
Methods and analysis
In this prospective, randomised, open-label, blinded end-point study, we will use h...
Source: BMJ Open - April 29, 2022 Category: General Medicine Authors: Huang, Y.-C., Chang, C.-H., Tsai, Y.-H., Weng, H.-H., Lin, L.-C., Lee, J.-D. Tags: Open access, Neurology Source Type: research
